MabVax Therapeutics Holdings Inc
MabVax Therapeutics — Investor Presentation (May 2015)
24 slides from MabVax Therapeutics's investor presentation, May 27, 2015
Slide 1: MabVax Therapeutics Corporate Presentation
Mi MabVax therapeutics OTCQB: MBVX Corporate Presentation
Slide 2: Disclaimer: Forward Looking Statements
Disclaimer Forward Looking Statements ‘This presentation contai s forward-looking statements and projections. The company makes no this information ot, in the f the project is i its own independent investigation. il is, her, or Tt must be recognized that estimates of the company actual results. In p
Slide 3: Investment Highlights
Investment Highlights aa cology secinolnes Substantial ‘Near-Term Clinical Pipeline Efficient Productive Well Managed Mivenvex Capital efficient development model company experience
Slide 4: Management Team and Board of Directors
Management Team and Board of Directors J:David Hansen Founder, President Board Member Mab Brace De Shang Plough, Key BM Philip Livingston, MD. Founder & Chief Science Officer Gregory Hanson Chief Financial Officer Wolfgang Scholz, PhD. Found & Vie President Antibody Discovery Paul Maffuid, Ph.D. Vie
Slide 5: Capital Efficient Business Model
Capital Efficient Business Model less intensive Mivenvex 5
Slide 6: Robust Pipeline with Multiple Near-Term Milestones
Robust Pipeline with Multiple Near-Term Milestones PreIND | Phase | Phase? | Phase} NNSKCG Patheon NILASKC, | Patheon Metasttie Pancreatic | Heidelberg Pharma -—D> 187/389 Saroma & MSKCC | ae i Vaccine Program lo <x _——— ‘Pentavalent Vaccine | ‘Ovarian Cancer MSKCC,NCL,GOG | | MSKCC, NANT, NCL Mimte
Slide 7: Antibody Program
D; Antibody Program liv-h: the
Slide 8: Antibody Discovery Technology Leverages Immune Response
Antibody Discovery Technology Leverages Immune Response From Many Vac Ca Tye f est Antibody Cloned & Expressed ‘As Monoclonal Mivenvex ivered vat Patients (Rar — ge 7 to 68) Each Patient Immune Best Antibodies Identified a a ONS 5 Sete Genentes Yrs se to Vaccine Patient Receives Fully-Human Best Ant
Slide 9: Validated Antigen Targets Expressed On Solid Tumor Cancers
Validated Antigen Targets Expressed On Solid Tumor Cancers ry carbohydrate targets —— F502 OO: Sr OOS = Sine pre Sooo Sa og a SS Sep 55 7 SD ODS oe 7 oO oe Discor, 2010 969): p 30828 Mivenvex
Slide 10: Lead Antibody Program Meets Need In Metastatic Colon Cancer
Lead Antibody P: M . Need In Metastatic i d Colon Cancer attractive molecular target = Increased expression correlated to poor survival! ~ Start Phase I clinical trial in 2015 ‘MabVax’s vaccine alive ‘oan 197 weeks post vaccination) 1 il, Sag AsO, Meal, Immo te atm te 38283), 2 Personal ss 2 commeni
Slide 11: HuMab 5B1 Clinical Candidate Selection
HuMab 5Bi1 Clinical Candidate Selection S$ ¢# HuMab 5B1-T1: Lead 5B1 v Y Potent cancer cell killing “ , , Y Active as antibody drug conjugate a ; ¢ Zr-HuMab 5B1: Lead 5B1 Program Diagnostic Antibody g : , : Mivenvex
Slide 12: HuMab 5B1-PET Improves Imaging Compared To Standard
HuMab 5B1-PET Improves Imaging Compared To Standard Agent In Use Today —$—_—_— Journal of Nuclear Medicine pancteatic tumor xenografts (Nov. 2013) Te cae of FCTET sl comp Acie 2 abel SB nods 0750) tomography (CD) il pliar sections of ape of he sane mouse coer ih FOCI ony ht cape ical mer CF esc exer
Slide 13: $1 Billion Market For New Pancreatic And Colon Cancer Treatment
For New Mi Pancreatic $1 Billion And Colon Cancer Treatment _—— impacts of treatment of pancreatic cancer Significant Number of New 7 Pa _ i Messe "Seiten Potential Patient Population Market Opportunity Relevant patient tease Pancreat nial 16,945 population exceeds 96,000 Taran — now pts per i Colon
Slide 14: MabVax and Juno T-cell Agreement
Ria 'T J T-cell Agreement MabVax and Juno MSKCC Mivenvex 4
Slide 15: Therapeutic Vaccine Program
Therapeutic Vaccine Program
Slide 16: Sarcoma Vaccine POC Phase II Results Due 1H2016
Sarcoma Vaccine POC Phase II Results Due 1H2016 ‘Sarcoma Incidence And Prevalence — 5,290 deaths per year in es snence E68 Up t0 2; Ss suviine Patents new cos Clinical Program Status of 136 patients at 13 sites ly enrolled with all patients fully vaccinated vival — Full = Monitoring for overall sur
Slide 17: Ovarian Vaccine POC Phase II Results Due 1H2016
Ovarian Vaccine POC Phase II Results Due 1H2016 Prevalence — 13,850 deaths per year in the US. sung Patents new Cases ¢ Clinical Program Status — Fully enrolled and all patients vaccinated = Monitoring for overall survival ¢ Commercial Opportunity non-recombinant components M MabVers
Slide 18: Neuroblastoma Vaccine Program IND 2H2015
Ni i ine Program IND 2H2015 ¢ Difficult disease = 700 new cases per year US remission — Treatment well tolerated ¢ Transition to Phase 2 Clinical Trial YA in 2014 Orphan Drug status granted by = Single study approval possible = Launch Phase II study 2H2015 (Cl Cans Res 2014:2021375-1382. bled Fray 1
Slide 19: Robust Intellectual Property
Robust Intellectual Property cancer
Slide 20: Milestones
Milestones Product HuMab 5B1- Therapeutic HuMab 5B1- PET Imaging HuMabsB1- ADC HuMab 1B7/31F9 Sarcoma Vaccine Program Ovarian Vaccine Program ‘Neuroblastoma ‘Vaccine Program M Mabyens + comple IND ening rocesiogy eso 1 Cope curtains + Opie sod + Couple prin ein 1 oni pasents or ned + GMP mms hetnDan
Slide 21: Discovery Company With Near-Term Milestones
Di i company With Near- Term Milestone: with significant commercial potential ign Ps therapeutic products (end of 2015) MabVax Therapeutics Holdings, Inc. OTCQB: MBVX Mivenvex
Slide 22: Investment Highlights
Investment Highlights aa cology secinolnes Substantial ‘Near-Term Clinical Pipeline Efficient Productive Well Managed Mivenvex Capital efficient development model company experience
Slide 23: MabVax Company Contacts
MabVax therapeutics A Company Company Contacts Gregory Hans Chief Financial Officer [email protected] [email protected] 158-259-9405 x 3 858-259-9405 x 303
Slide 24: Current Capitalization Table
Current Capitalization Table Miyeover series retered tock vata ess srs pretred stooe sequent vent [art a205- amos [omormecreaoeens ————] Ramon stack nsessis sre pretered tock an vant aiseco series preter sto sdseqvnt event forte 2018" lavas Sans Jsmmonseckat 1500 sure ope recon 2.09 687 pce protecti
MabVax Therapeutics Holdings — Investor Presentation (May 2015) on 6ix